Drug Profile
Research programme: RWJ 445167 prodrugs - Johnson & Johnson
Latest Information Update: 02 Sep 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Guanidines
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 02 Sep 2016 No development reported - Preclinical for Thrombosis in USA (PO)
- 02 Sep 2016 Preclinical trials in Thrombosis in USA (PO)